 Connection
Paul Bunn to Immunotherapy
This is a "connection" page, showing publications Paul Bunn has written about Immunotherapy.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.938 |
|
|
|
-
Peled N, Oton AB, Hirsch FR, Bunn P. MAGE A3 antigen-specific cancer immunotherapeutic. Immunotherapy. 2009 Jan; 1(1):19-25.
Score: 0.241
-
Schenk EL, Patil T, Pacheco J, Bunn PA. 2020 Innovation-Based Optimism for Lung Cancer Outcomes. Oncologist. 2021 03; 26(3):e454-e472.
Score: 0.138
-
Bunn PA. Immune therapy for lung cancer: are we getting closer? Am J Respir Cell Mol Biol. 1999 Jul; 21(1):10-2.
Score: 0.125
-
Bunn PA, Schenk E, Pacheco J, Dimou A. New Developments in Neoadjuvant Therapy for Lung Cancer. Oncology (Williston Park). 2019 Mar 13; 33(3):101-6, 109.
Score: 0.122
-
Hirsch FR, Kerr KM, Bunn PA, Kim ES, Obasaju C, P?rol M, Bonomi P, Bradley JD, Gandara D, Jett JR, Langer CJ, Natale RB, Novello S, Paz-Ares L, Ramalingam SS, Reck M, Reynolds CH, Smit EF, Socinski MA, Spigel DR, Stinchcombe TE, Vansteenkiste JF, Wakelee H, Thatcher N. Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. Clin Lung Cancer. 2018 07; 19(4):331-339.
Score: 0.114
-
Tsao AS, Scagliotti GV, Bunn PA, Carbone DP, Warren GW, Bai C, de Koning HJ, Yousaf-Khan AU, McWilliams A, Tsao MS, Adusumilli PS, Rami-Porta R, Asamura H, Van Schil PE, Darling GE, Ramalingam SS, Gomez DR, Rosenzweig KE, Zimmermann S, Peters S, Ignatius Ou SH, Reungwetwattana T, J?nne PA, Mok TS, Wakelee HA, Pirker R, Mazi?res J, Brahmer JR, Zhou Y, Herbst RS, Papadimitrakopoulou VA, Redman MW, Wynes MW, Gandara DR, Kelly RJ, Hirsch FR, Pass HI. Scientific Advances in Lung Cancer 2015. J Thorac Oncol. 2016 05; 11(5):613-638.
Score: 0.099
-
Bunn P, Carbone D, Grim J, Harris C, Havemann K, Mabry M, Roth J, Saijo N, Poulsen HS, Stahel R, Takahashi T, Twentyman P. Fifth I.A.S.L.C. Lung Tumor Biology Workshop, August 13-17, 1996, Ermatingen, Switzerland. Ann Oncol. 1997 Jan; 8(1):27-36.
Score: 0.026
-
Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, Goldberg SB, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. J Thorac Oncol. 2015 Jan; 10(1 Suppl 1):S1-63.
Score: 0.023
-
Bunn PA, Hoffman SJ, Norris D, Golitz LE, Aeling JL. Systemic therapy of cutaneous T-cell lymphomas (mycosis fungoides and the S?zary syndrome). Ann Intern Med. 1994 Oct 15; 121(8):592-602.
Score: 0.023
-
Beck LK, Kane MA, Bunn PA. Innovative and future approaches to small cell lung cancer treatment. Semin Oncol. 1988 Jun; 15(3):300-14.
Score: 0.014
-
Bunn PA, Cohen MH, Ihde DC, Fossieck BE, Matthews MJ, Minna JD. Advances in small cell bronchogenic carcinoma. Cancer Treat Rep. 1977 May-Jun; 61(3):333-42.
Score: 0.007
-
Foon KA, Schroff RW, Bunn PA, Mayer D, Abrams PG, Fer M, Ochs J, Bottino GC, Sherwin SA, Carlo DJ, et al. Effects of monoclonal antibody therapy in patients with chronic lymphocytic leukemia. Blood. 1984 Nov; 64(5):1085-93.
Score: 0.003
-
Morstyn G, Ihde DC, Lichter AS, Bunn PA, Carney DN, Glatstein E, Minna JD. Small cell lung cancer 1973-1983: early progress and recent obstacles. Int J Radiat Oncol Biol Phys. 1984 Apr; 10(4):515-39.
Score: 0.003
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|